Asset profile
apitegromab
Monoclonal antibody
Evidence outlook · lead readout
NCT06445075 · Overweight and Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06445075: The study randomized 102 participants to apitegromab plus tirzepatide or placebo plus tirzepatide and used quadruple masking, including blinded participants, clinicians, investigators, and outcome assessors. Its primary endpoint was change in lean body mass measured by DXA, a body-composition surrogate rather than a hard clinical outcome, and no primary-endpoint result has been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.